MEDIUM confidence
Researched 2026-08-04 20:42 · profile: startup
Programme Thesis
The DayOne Accelerator Program funds early-stage healthtech and techbio startups focused on pharmaceutical R&D, providing an equity-free, fee-free three-month hybrid program in Basel to accelerate innovation in drug discovery and development. It exists to attract global innovators to the Basel life sciences hub, offering non-dilutive funding and infrastructure support to help them grow without diluting ownership.
Selection Criteria
- Early-stage startup (pre-seed to Series A) with less than USD 10 million in dilutive funding raised.
- Focus on healthtech or techbio, specifically enhancing pharmaceutical R&D processes.
- Global eligibility; international teams encouraged.
- Potential for high performance and impact; selected ventures may receive up to CHF 50,000 in non-dilutive funding post-program.
- Willingness to participate in hybrid program with in-person bootcamp in Basel (travel support up to CHF 1,000).
- Alignment with Basel life sciences ecosystem and potential for partnership development.
Past Winners / Cohort Profiles
The page content does not list specific past winners. However, based on the program's focus, past cohorts likely include early-stage healthtech and techbio startups working on drug discovery, clinical trial optimization, or digital health solutions, with a mix of international founders seeking to establish a presence in Basel.
Ideal Candidate Fingerprint
The ideal applicant is a pre-seed to Series A healthtech or techbio startup with a clear focus on improving pharmaceutical R&D, having raised less than USD 10 million. They should have a validated proof-of-concept, a strong team, and a scalable solution that can benefit from Basel's life sciences ecosystem. The startup should be open to hybrid participation and eager to leverage non-dilutive funding and office space to accelerate growth.
Recommended Framing
For Eniola Olutogun, the strongest angle is to position the venture as a techbio startup directly enhancing pharmaceutical R&D by predicting drug resistance mutations from protein sequence alone, which is a critical bottleneck in drug development. The venture's technology (ESM-2 delta-embeddings + ECFP4 fingerprints) is a perfect fit for the program's focus on pharma R&D innovation, and the non-dilutive funding and Basel network would support the roadmap toward the Servier pilot and ARR. Emphasize the 100% mutation coverage and superior AUROC vs. structure-limited tools to highlight the competitive edge.
Watch Out
The venture is not yet incorporated, which may be a concern for some accelerators; however, the program's eligibility does not explicitly require incorporation. Also, the program is based in Basel, Switzerland, so the hybrid format and potential travel requirements should be considered. The venture's focus on computational biology is a strong fit, but the program may favor startups with a more direct clinical or lab-based component.